Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer trims obesity pipeline, axes phase 2 lung disease asset
Pfizer has axed a pulmonary arterial hypertension program, dealing a setback to a long-running effort to treat the lung disease by targeting BMP9.
Nick Paul Taylor
Nov 3, 2026 8:02am
Pfizer makes 'business decision' to end trial of autoimmune drug
Oct 20, 2026 6:59am
Pfizer pens $500M Enodia pact to join Lilly in emerging field
Oct 13, 2026 7:00am
Pfizer offloads scrapped Seagen ADC to Medicus Pharma
Sep 3, 2026 11:31am
Pfizer axes ex-Metsera obesity asset and GIPR prospect
Aug 4, 2026 8:47am
US lawmakers’ focus on China trials risks ‘huge distraction’
Jul 7, 2026 10:30am
